Molecular Templates Announces Participation in Four Upcoming Conferences

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences. Presentation links can be found in the “News and Media” section of the corporate website. One-on-one meetings may be scheduled via conference representatives or directly with Molecular Templates.

  • Citi 17th Annual BioPharma Conference, September 7 – 8, 2022

    Location: Boston, MA
  • H.C. Wainwright 24th Annual Global Investment Conference, September 12 – 14, 2022

    Location: New York, NY

    Webcast Presentation: September 12, 2022, available starting 7am ET here
  • Morgan Stanley 20th Annual Global Healthcare Conference, September 12 – 14, 2022

    Location: New York, NY
  • Cantor Oncology, Hematology, and HemeOnc Conference, September 28, 2022

    Location: New York, NY

    Live Panel Presentation: “Innovation is the Name of the Game: Novel Modalities for Oncology”, September 28, 9:50am – 10:30am ET

About Molecular Templates

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “potential,” “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including MT-6402 and MT-5111, Molecular Templates’ beliefs regarding the anticipated benefits of MT-6402, MT-5111, MT-0169, and MT-8421 and Molecular Templates’ next-generation ETBs; statements relating to the development of MT-6402,MT-5111, MT-0169 and MT-8421, and next-generation ETBs; the expected timing of submitting various IND applications and conducting studies, opening sites and generating data; the expected participation and presentation at upcoming conferences; the expected timing for providing updates on MT-6402, MT-5111, MT-0169, and MT-8421, as well as Molecular Templates’ earlier stage pipeline of ETBs including any pre-clinical data; and Molecular Templates’ belief that its proprietary biologic drug platform technology of ETBs, provides for a differentiated mechanism of action from Antibody Drug Conjugates (ADCs) that may address some of the limitations associated with currently available therapeutics for cancer and other serious diseases.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates’ cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Dr. Grace Kim
Head of Investor Relations


Primary Logo

Source: Molecular Templates, Inc.